GlaxoSmithKline (GSK) has released an update.
GlaxoSmithKline (GSK) has announced that the US FDA has granted priority review for the expansion of Jemperli (dostarlimab) in combination with chemotherapy for all adult patients with advanced or recurrent endometrial cancer, after showing significant survival benefits in the phase III RUBY trial. The FDA decision is set for 23 August 2024. Jemperli is already approved for certain endometrial cancer patients, and the new indication could significantly extend its use.
For further insights into GSK stock, check out TipRanks’ Stock Analysis page.
